Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 25;18(3):180-185.
doi: 10.1177/1753495X241263135. eCollection 2025 Sep.

Prediction of obstetric outcomes in sickle cell patients based on tricuspid regurgitant velocity

Audrey Lacasse  1 , Vincent Williams  1 , Pallavi Ganguli  2 , Sophie Grand'Maison  1   2   3 , Bilan Wo  3   4 , Veronique Cyr  5 , Marie-Lou Tardif  6 , Nadia Caron  7 , Julien Viau-Lapointe  8 , Veronique Naessens  9 , Michele Mahone  1   2   3
Affiliations

Prediction of obstetric outcomes in sickle cell patients based on tricuspid regurgitant velocity

Audrey Lacasse et al. Obstet Med. .

Abstract

Background: Transthoracic echocardiography, a validated tool for risk assessment in non-pregnant population with sickle cell disease (SCD), uses tricuspid regurgitant velocity (TRV) over 2.5 m/s is an independent mortality risk factor. Its applicability in obstetrics lacks sufficient evidence.

Methods: In this multicenter retrospective cohort study across five tertiary centers, we aimed to validate TRV as a determinant of increased maternal and fetal risk. Data was collected on 93 women and included 21 patients with TRV of at least 2.5 m/s. The maternal primary composite outcome included occurrence of vaso-occlusive crisis, acute chest syndrome, gestational hypertension, preeclampsia, and mortality. The fetal primary composite outcome comprised perinatal mortality, premature delivery, reduced birth weight, and fetal distress.

Results: Adverse maternal and fetal events arose in both groups with no statistical difference.

Conclusion: This study cannot support TRV of 2.5 m/s or more as an independent predictor of adverse obstetric outcomes among women with SCD.

Keywords: Pregnancy complications; hematologic.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Study cohort.
See this image and copyright information in PMC

References

    1. Katsuragi S, Yamanaka K, Neki R, et al. Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. Circ J 2012; 76: 2249–2254. - PubMed
    1. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30: 256–265. - PubMed
    1. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365: 44–53. - PubMed
    1. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006; 134: 109–115. - PubMed
    1. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005; 19: 881–896. - PubMed

LinkOut - more resources